Eli Lilly plans to seek FDA approval for retatrutide, its next-generation obesity drug, after fresh trial data confirmed some of the strongest weight-loss results the field has seen.
Retatrutide is a “triple-G” agonist — it acts on three hormone receptors (GLP-1, GIP, and glucagon), one more than Lilly's current blockbuster tirzepatide (Mounjaro, Zepbound) and two more than Novo Nordisk's semaglutide (Ozempic, Wegovy).
What the new data show
Lilly announced results on July 23 from two late-stage studies. In Triumph-2, patients with type 2 diabetes lost an average of 21% of their body weight after 80 weeks. In Triumph-3, a group with cardiovascular disease lost about 23% at the highest doses. Those figures are lower than the roughly 30% seen in the earlier Triumph-1 trial after 104 weeks — but they came in patients with underlying conditions, and Lilly said they met expectations.
When could it reach patients?
Lilly said it plans to file with the FDA in the first quarter of 2027. The timeline slipped from earlier expectations, partly because of the manufacturing and quality-control data regulators require for a drug likely to be in enormous demand.
Why it matters
If approved, retatrutide would raise the ceiling on how much weight a medicine can help patients lose — deepening Lilly's lead in a market already worth tens of billions. For patients, more options and greater efficacy are welcome, but bigger effects can also mean more side effects, and these drugs remain expensive and often hard to access. Weight-loss decisions should be made with a doctor. This article is general information, not medical advice.